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Abstract
Background: In 2014, a qualitative multi-country research project was launched to study the reasons behind the
high use of antibiotics in regions of Southeast Europe by using previously untrained national interviewers (who were
engaged in other antibiotic microbial resistance-related investigations) to conduct qualitative interviews with local
patients, physicians and pharmacists. Little knowledge exists about how to implement qualitative multi-country
research collaborations involving previously untrained local data collectors. The aim of this paper was therefore to
contribute to the knowledge regarding how to conduct these types of research projects by evaluating a pilot study
of the project.
Methods: Local data collectors conducted the study according to a developed protocol and evaluated the study with
the responsible researcher-team from University of Copenhagen. The pilot study focused on ‘local ownership’, ‘research
quality’ and ‘feasibility’ with regard to successful implementation and evaluation. The evaluation was achieved by
interpreting ‘Skype’ and ‘face to face’ meetings and email correspondence by applying ‘critical common sense’.
Results: Local data collectors achieved a sense of joint ownership. Overall, the protocol worked well. Several minor
challenges pertaining to research quality and feasibility were identified, in particular obtaining narratives when
conducting interviews and recruiting patients for the study. Furthermore, local data collectors found it difficult to
allocate sufficient time to the project. Solutions were discussed and added to the protocol.
Conclusions: Despite the challenges, it was possible to achieve an acceptable scientific level of research when
conducting qualitative multi-country research collaboration under the given circumstances. Specific recommendations
to achieve this are provided by the authors.
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Background
For decades, a considerable number of research collabo-
rations have been launched between western and non-
western partners with the aim of improving health in
emerging economies. Several critical factors have been
identified in this regard, including (too little) attention to
local priorities, feasibility, capacity building, pilot studies,
stakeholder support, refinement of research protocols and
information systems, and ethical issues [1–3].
Research on antimicrobial resistance is one contempor-
ary health area in which partnerships between different
countries have been established. For example, the World
Health Organization (WHO) Regional Office for Europe
has undertaken numerous initiatives in different locations,
including in the region of Southeastern Europe. One initia-
tive includes the continuous surveillance of antibiotic (AB)
drug consumption. Systematic surveillance measurements
and publications of antimicrobial consumption within the
European setting began with the ESAC initiative with EU
countries [4], but data on AB consumption are now also
being collected through the management of the Health
Technologies and Pharmaceuticals group (HTP), the WHO
Regional office for Europe in non-EU Southeast European
countries. Through this effort, it has been documented
that a high level of inappropriate AB use is present in
this region [5].
To determine the reasons for inappropriate AB use and
trends in consumption in this area, it has been suggested
to supplement consumption data with additional data on
prescriptions and to collect detailed information about
national programmes and campaigns on the prudent use
of antimicrobials [6]. Another useful approach to under-
standing the reasons for the inappropriate use of AB is to
apply qualitative research. Hence, in 2014, an additional
qualitative research project in the geographical area of
Southeast Europe was launched with the aim of investigat-
ing the AB use culture, i.e., the knowledge, attitudes and
actual behaviours of patients and health care practitioners,
to inform individual countries on how to target future
interventions. Countries already engaged in the WHO AB
consumption data collection group in the non-EU South-
east European region were invited to take part in the
qualitative project with the role of becoming the primary
data collectors i.e., local project facilitators. Originally, 17
countries participated in the AB consumption data col-
lecting group [5], and the group has now been expanded
to include 19 countries in total.
There are many advantages to having local countries con-
duct qualitative research. First, there are no language bar-
riers. This enables a dialogue with all relevant stakeholders
in the country without the use of interpreters, as the use of
interpreters has been shown to reduce validity [7]. Another
advantage is that locally based research is more sensitive to
capturing local practices and ideas. However, in qualitative
studies, the researcher becomes the data collection instru-
ment. In general, the results therefore depend more on the
skills of the researcher when compared with quantitative
instruments such as surveys, in which questions and cat-
egories of answers are pre-determined and standardized.
The qualitative project was managed by researchers
from the Section of Social and Clinical Pharmacy at the
University of Copenhagen (SSC). The SSC has decades
of experience in conducting research projects employing
qualitative methods within the field of medicine use [8].
Knowledge exists on how to develop research collabora-
tions between partners, such as academic researchers
and practitioners, in different countries [9, 10], including
for qualitative projects [11]. However, we found little
information regarding how to implement qualitative re-
search collaborations involving up to 19 countries using
local data collectors, most of whom were expected to be
previously untrained in qualitative methods.
The aim of this paper is therefore to contribute to the
knowledge on how to conduct qualitative multi-country
research projects under the aforementioned settings. The
information was obtained through a pilot study and there-
fore illustrates our experiences conducting the qualitative
AB project in Albania, Kosovo and Turkey.
Methods
In our attempt to ensure successful implementation of
the qualitative AB multi-country project, we decided to
focus on three particular factors [10]:
– Local ownership (acceptability)
– Research quality (implementation)
– Feasibility (practicalities)
Local ownership was a priority to ensure that local pro-
ject facilitators considered the project relevant and that they
could achieve valuable knowledge by participating in the
project. Because the goal of the project was to enable coun-
tries to make informed interventions, it was also essential
that the research results were of an acceptable quality.
Finally, feasibility was important. Most facilitators had no
previous experience conducting qualitative research and
were often busy carrying out other jobs simultaneously. As
a result, it was necessary to develop and evaluate these ele-
ments through a pilot study.
Measures to ensure local ownership, research quality and
feasibility
To generate local commitment, the first step of the project
took place in 2014 in Slovenia when the project was
presented to a group of countries in the Balkan area of
Southeastern Europe. Seven countries participated, and the
attendees were primarily health care professionals (typic-
ally pharmacists and pharmacologists) working at national
Kaae et al. Journal of Pharmaceutical Policy and Practice  (2016) 9:20 Page 2 of 10
medicine agencies and universities. Three countries volun-
teered to run the pilots: Albania, Kosovo and Turkey.
The SSC decided that semi-structured interviews should
be the applied method for investigating AB knowledge,
behaviour and attitudes of patients and health care profes-
sionals. The SSC made several other initial decisions on
how to conduct the study, taking into consideration the
aspects of local ownership, research quality and feasibility
(please see Table 1) [5, 12–14]. The decisions were
accounted for in a protocol to align the research con-
ducted by the local facilitators in different countries.
To adequately assess the culture of patients and health
care professionals as it related to AB use, the protocol
specified the themes within AB use that were to be ex-
plored in the interviews. The protocol further specified
the research questions pertaining to each of these themes
and contained the operationalized forms of these research
questions, i.e., the interview guides (please see Table 2 as
well as Appendix 1 for one example of an interview
guide). The themes were based on previous literature [15]
and discussions with experts in the field of rational AB
use (please see acknowledgements).
Table 1 Initial decisions and rationale to ensure ownership, research quality and feasibility (before conducting the pilot evaluation)
Decision Rationale with respect to: local ownership/feasibility/research quality
Data collection and transcriptions should be completed by national
project facilitators
Local ownership
Local participants carry out and transcribe the conducted interviews to
create local ownership and specific insight into how future interventions
could be targeted.
General practitioners (GP) and community pharmacists who prescribe
or sell antibiotics should be interviewed
Research quality
Interviews with GPs were supplemented with interviews with community
pharmacists due to their role in dispensing/informing patients about
antibiotics in general and the documented practice of providing
antibiotics without a prescription in community pharmacies in some
countries in Southeast Europe (Hoxha et al.).
Patients interviewed should be adults who have suffered from an
infection within the previous 3 months that they treated with
antibiotics (with or without a prescription)
Research quality
Adults were chosen to ensure a minimum comparability of data
(antibiotic use by children is believed to contain other aspects, especially
regarding attitudes – Wun et al.). A 3 month limit was selected to reduce
memory bias. Both patients with and without prescriptions should be
included, as the high antibiotic consumption could be caused by both
groups (Mitsi et al.).
Infections should consist of only upper respiratory tract infections Research quality
The area of infection was specified to ensure comparability of data.
Furthermore, upper respiratory tract infections are common diseases,
hence constituting an ideal case to study the typical reasons behind high
antibiotic consumption with regard to knowledge, attitudes and
behaviour.
Specific antibiotics to be investigated were: amoxicillin-clavulanic acid,
azithromycin, ciprofloxacin and ceftriaxone
Research quality
Specific antibiotics were selected to ensure the comparability of data. The
four antibiotics selected have all been shown to be used irrationally in
the region of Southeastern Europe (Versporten et al.), with a risk to public
health, as most are broad spectrum. A few deviations to this could be
tolerated if the ABs were not used in a specific country.
Three interviews should be conducted within the four groups of
interviewees: patients with a prescription, patients without a prescription,
GPs and community pharmacists; hence, 12 interviews total per country.
The patient interviews should contain a detailed description of the last
time the interviewee was prescribed/bought an antibiotic. Interviews
with health care professionals should address detailed descriptions of 3
specific episodes during the last week in which they handled antibiotics.
All specific incidents should further be explored in relation to the way
the relevant parties usually prescribe/purchase or prescribe/sell antibiotics
Feasibility and research quality
The number of interviews was designed to maintain a decent workload
balance for the participants, yet it was expected that it would be possible
through data triangulation of the 12 interviews to detect condensed patterns
of antibiotic knowledge, attitudes and behaviour. Antibiotic knowledge,
behaviour and attitudes can best be derived through detailed narratives,
which are more easily obtained when they address specific recent incidents.
To ensure that this recent incident represented typical behaviour, its
resemblance to former similar situations was also explored. As the number of
AB episodes described in the interviews that would be used in the data
analysis was therefore at least 24 (6 from patients and 18 from health care
professionals), it was estimated that data saturation could then be achieved
regarding aspects of AB use.
Data analysis should be conducted in collaboration between the
Section for Social and Clinical Pharmacy and local facilitators
Research quality
Combining the analytical competencies of the researchers from
Copenhagen with detailed knowledge of the local culture of local
facilitators was assessed as being the most ideal way of achieving high
quality results.
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Finally, the protocol included practical guidance on how
to recruit participants, how to conduct and transcribe the
interviews and how to perform the first steps of the analysis
(content analysis). Regarding recruitment, the protocol de-
fined 4 groups that had to be interviewed, i.e., adults who
were either patients or health care professionals, and delin-
eated the research area into four specific ABs used for
upper respiratory tract infections (URTIs). The use of the
four selected ABs had been found to be particularly con-
cerning in the quantitative consumption study [5], which is
why they were considered interesting to investigate in
depth; additionally, limiting the number of included ABs
would increase the comparability of the data within the
same country and between countries with regard to know-
ledge, attitudes and practices. The patients interviewed
should have used one of the selected ABs for a URTI within
3 months, whereas the health care professionals (commu-
nity pharmacists and general practitioners) were asked to
recall 3 episodes in the last week in which they had man-
aged some of the specified ABs for a URTI. The local data
facilitators were encouraged to recruit participants with
variations in gender, age and education and were further
asked by the SSC to consider if they were in need of further
inclusion criteria (for example: specific geographical areas,
ethnic groups, language, etc.). Different sampling proce-
dures were suggested, one of which was the snowball tech-
nique in which one’s professional and/or private networks
are used to identify people who fulfil the inclusion criteria.
It was emphasized that if this sampling procedure was used,
it was not recommended for interviewers to interview
people they knew personally. It was recommended in the
protocol to make an appointment with patients to interview
them some days after receiving their AB to investigate how
they took the medicine. The protocol highlighted the eth-
ical criteria involved in each step.
The protocol was written in English. As the interviews
were conducted in the national language, this required
both the translation of the developed interview guides
into the local language and the translation of the tran-
scripts of the conducted interviews back into English.
The pilot project
Two-day pilot training seminars were carried out in
November 2014 and January 2015 to ensure that the
protocol initially developed by the SSC covered key aspects
of the AB use culture as perceived by the pilot countries’
facilitators. Furthermore, the seminars were designed to
train country facilitators to conduct the interviews. This
was achieved by training them in the basics of qualitative
research and ensuring that the SSC and the pilot countries
had an aligned understanding of the content of the research
questions in the protocol and interview guides.
Following the training sessions, each pilot country was
instructed to conduct, transcribe and translate 3 interviews
within each of the four groups of interviewees (patients
who had recently had an AB prescription, patients who had
recently bought an AB without a prescription, physicians
and community pharmacists) according to the protocol.
Approximately 4 months after collecting the data, the
pilot countries met with the SSC to complete the content
analysis of the collected data.
Evaluation
The pilot countries provided written and oral feedback on
their experiences using Skype meetings, e-mail communi-
cation and face-to-face discussions. The feedback was fo-
cused on local ownership, research quality and feasibility:
Local ownership: Assessing if and how the participating
countries experienced ownership of the project. As the
SSC had taken the lead to form the project, it had to be
ensured that this initiative did not undermine the commit-
ment of the pilot facilitators.
Table 2 Relation between research themes, research questions
and interview guides
Themes in the protocol to be explored by the project
- The process of diagnosis
- Why a specific antibiotic was selected
- Where and how antibiotic were purchased
- Use of antibiotic,
- Satisfaction with antibiotic process
- Antibiotic knowledge
- Antibiotic attitudes
Example - Research questions pertaining to the theme ‘The process of
diagnosis’
- What symptoms made the patient seek the physician or the
pharmacist?
- What did the patient want from the consultation?
- What did the patient expect from the consultation?
- Was the patient examined? If yes - how?
Example - Operationalized research questions in the interview-guide
pertaining to ‘The process of diagnosis’ (‘Patients with AB prescription’-
please see appendix 1 for the full interview guide):
- When was the last time you got a prescription for an upper respiratory
tract infection (should be within the last 3 months)
- What was the situation – what were your symptoms – for how long?
- Did you have any idea what kind of disease you were suffering from?
- Did you come here by your own initiative or were you encouraged by
family, colleagues or friends?
- Which doctor did you seek – why this doctor?
- What did you want from the doctor?
- What did you expect from the doctor?
- How did the consultation go? What happened? What was said – by
whom?
- Did the doctor make a diagnosis/examine you? If yes, how and do you
know what the diagnosis was?
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Research quality: Assessing interview transcripts ac-
cording to the principles of qualitative research, espe-
cially the skill to obtain narratives that provided
coherent and detailed stories of interviewees’ experi-
ences with AB [16]. For example, a full description of
how patients purchased an AB in a pharmacy without a
prescription would inevitably contain aspects of the
patients’ knowledge and attitudes towards AB as well as
both their and the pharmacists’ typical behaviour and
social interactions.
Feasibility: Assessing challenges experienced with regard
to the recruitment process, carrying out the interviews,
documentation and analysis as well as an evaluation of the
workload of facilitators.
The assessment was completed by the SSC and was
based on the analytical principle of “critical common
sense”, which Kvale describes as “interpretations that can
be broader than the understanding of the interviewee
him/herself, i.e., critically assess what is said” [17].
Based on the evaluation, the SSC and pilot countries
discussed different solutions to the identified challenges.
Consensus was reached, and improvements were incor-
porated into the protocol (please see Fig. 1 under the
heading October 2014 - Slovenia - there are some gabs
between workds missing and an 'i' before 'idea' is missing
for a full overview of the different steps of the pilot
study).
Ethics
No ethical approval was needed for the pilot evaluation
as it consisted of the opinions and experiences of the au-
thors of this article. However, the Danish Data Protec-
tion Agency has been approached in relation to the
management and later publication of the data collected
from the pilot projects.
Results and discussion
Local facilitators in the pilot study achieved a sense of
joint ownership. The protocol, including the interview
guides, worked well. Several minor challenges pertaining
to the research quality and feasibility were identified.
These challenges were either a) challenges of qualitative
research in general or b) challenges specific to conducting
qualitative research in multi-country settings. In the fol-
lowing section, the challenges and solutions are presented
and discussed in relation to methodological reflections on
conducting qualitative research.
Local ownership
The facilitators expressed feelings of joint ownership
over the project. They stated that the interview guides
and the project made sense to them partly as a result of
having had the opportunity to provide feedback on the
protocol initially developed by the SSC. They expressed
a feeling of ownership over the data they provided, but
not over the research process. They saw the project as a
collaboration between three parties: the WHO, the SSC
and their own country, and each party had a specific role
to fulfil. The pilot countries were comfortable with this
division of tasks.
The facilitators also felt that conducting the interviews
had mostly confirmed their preconceived perceptions of
the culture surrounding patients’ and health care profes-
sionals’AB use. However, in some cases, the data collection
process led to new insights; for example, some facilitators
were surprised to learn that many patients were aware that
Spring 2014 
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Fig. 1 Overall depiction of the different steps of pilot study
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ABs should only be used in some occasions. Finally, the
facilitators stated that working in an open multi-country
collaboration setting was helpful as they could discuss and
learn from each other.
Research quality
Challenges to research quality were identified. A general
problem with interview flow was identified. Moreover,
one specific challenge that arose was that the project
facilitators in the pilot countries did not always manage
to obtain narratives. Collaboration between the pilot
countries and the SSC was found to be fruitful when
analysing the data.
General challenges – flow of interviews
Facilitators felt that they had to repeat several questions,
especially when asking health care professionals to de-
scribe three episodes from the last week in which they
had managed AB use. According to the facilitators, this
hindered the overall flow of the conversation.
Solutions – flow of interviews
In semi-structured interviews, it is of utmost importance
for the interviewee “to talk freely and spontaneously about
their feelings, experiences, attitudes and behaviour” [18].
As a result of this expressed challenge, changes to the
interview guide were made. First, the number of recollec-
tions of specific AB episodes required by health care pro-
fessionals was reduced from 3 to 2 episodes. Additionally,
the facilitators suggested changing the order of questions
for health care professionals.
Specific challenges – obtaining narratives
Obtaining narratives was feasible. One example was the
story told by a father about his son, who had become ill.
The father took the son to a general practitioner (GP),
who concluded that the son was not ill enough to receive
ABs. The GP orally instructed the father that if the situ-
ation deteriorated, the father should go to the community
pharmacy and pick up a specific AB. The father was not
given a prescription and was not instructed on how to use
the AB should it become necessary to purchase it later on.
This example underlines the strength of recording nar-
ratives, as this short story provides insight into typical
AB behaviours (GP promoting the use of AB without a
prescription and some GPs appearing to provide only oral
instructions and no information on the dosing regimen).
The example also reveals underlying attitudes regarding
AB use (GP thinks that not all situations should be treated
with AB).
The transcripts also revealed that narratives were not
always obtained. The transcripts were different in terms of
the level of detail collected partly because not all local
researchers had been authorized to record the interviews.
However, even when recorded, narratives were not always
provided. This could be due to the study design, which
employed local facilitators who primarily had backgrounds
in natural sciences.
Solutions – obtaining narratives
It was decided that from a workload perspective, no further
interview training was feasible. Instead, the original proto-
col of 3 interviews within the 4 groups of interviewees (de-
signed to balance data quality with feasibility) was changed
to require 4 interviews per group. In this manner, more
information about the AB culture would be revealed, not
by conducting deeper interviews but by conducting more
interviews. This compromised the workload of the data
collectors but was necessary to ensure saturated themes
regarding AB use.
Despite raising the number of interviews from 12 to 16,
it was further deemed necessary to ensure the consistency
of data and the possibility of achieving data saturation by
having the interviewees address the same types of AB situ-
ations. The interview guides for the health care profes-
sionals were therefore revised, and they were now asked
to recall 2 typical examples of AB consultations (and not
just 2 consultations) during the last week.
Fruitful settings for analysing data
Coming from a different cultural context, the researchers
from the SSC could guide the process of analysis as well as
question the nuances of and reasons behind the AB know-
ledge, attitudes and behaviours revealed in the data. The
pilot facilitators could correct and expand upon the SSC
researchers’ understanding of the transcripts. Altogether,
the collaboration provided more results, as well as more
precise results, than if the parties had performed the ana-
lyses separately.
Feasibility
The materials developed for the project worked well,
and only minor adjustments had to be made. The major
practical obstacle for the pilot facilitators was difficulty
in recruiting patients. The local facilitators emphasized
that it was a challenge for them to devote as much time
to the project as they would have liked.
General challenges – recruitment of patients
Pilot facilitators used the snowball sampling technique to
recruit patients but found it difficult to recruit enough
patients. Furthermore, the facilitators discovered when con-
ducting the interviews that patients sometimes had other
types of infections that required ABs; however, due to a lack
of physiological knowledge, they had agreed to be inter-
viewed. There were no instances of incorrect recruitment
due to patients having used a different AB than requested.
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Solutions– recruitment of patients
The recruitment of participants is essential to the success
of research projects [18], and difficulties in recruitment
are common. Supplementing the snowball recruitment
technique by offering financial incentives for participating
patients was suggested. Using contacts at local community
pharmacies was suggested as another method. These sug-
gestions were added to the protocol.
To maintain a realistic workload balance for the facilita-
tors, the SSC decided to include a small number of inter-
viewed patients who were being treated for types of
infections other than URTI as well as a few cases when the
child was the one who was ill, as it was assessed that these
interviews could still provide useful answers to the research
questions.
General/specific challenges – interview guide
A few questions from the pilot countries were raised: a)
the specific importance of and difference between certain
questions in the interview guide and b) the experience
that some questions in the interview guide had negative
connotations. For example, the facilitators felt that it was
patronizing to ask the patients: “Can you explain what an
AB does in your body?”
These questions showed that the training sessions did
not ensure that all questions in the interview guides and
the nature of conducting qualitative interviews were under-
stood in the same way by the SSC and pilot facilitators.
Difficulties employing multiple interviewers can be found
in all qualitative projects [19]; however, in this scenario, the
challenge was likely reinforced by the multi-country setting.
Solutions – interview guide
Despite the recognition that a full acquisition of under-
standing between researchers is hard to achieve [19], it was
assessed that the specific issues raised could be resolved.
Hence, it was now explained more thoroughly in the proto-
col that interviewing allows for flexibility, for example, that
questions can be phrased differently as long as they facili-
tate answers that can be used to answer the research ques-
tions of the study.
The identified challenges underlined the importance
of closer contact between the SSC and the individual
countries to discuss challenges that local facilitators expe-
rienced while conducting the interviews.
Specific challenges – allocating time
The facilitators in the pilot studies found it challenging to
allocate a sufficient amount of time to the project. The local
data collectors required between 15 and 80 min for the
interviews (with some variation between the three pilot
countries), with interviews with patients often being shorter
than those with health care professionals. This timeframe
was in many cases found to be acceptable; however, in
some cases, this timeframe was too short, as some partici-
pants, especially patients, appeared to be in a hurry. Tran-
scribing and translating the transcriptions were perceived
to be the most time consuming tasks. This led pilot facilita-
tors to ask the SSC for tighter instead of looser deadlines. It
was therefore concluded that tighter timelines should be
implemented.
Limitations
We found both general and specific challenges with regard
to conducting qualitative research in a multi-country
setting; however, of these challenges, we identified only a
few that were caused by the specific topic – culture of AB
use. One such specific challenge that the pilot facilitators
experienced was that patients agreed to be interviewed
even when they suffered from the “wrong” infection or
when it was the child and not the adult who was ill (des-
pite these requests being stated in the protocol). In this
study, most of these interviews were considered to contain
valuable insight into the research questions and were
therefore included in the analysis; however, this decision
despite original intentions then to a small extent increased
the heterogeneity of some of the data. As topic-dependent
challenges were limited, we trust that most of the results
of our evaluation are transferable to other qualitative
multi-country research settings.
One study limitation that is probably transferrable to
other settings was that several of the interviewers worked
at national medical agencies, and it was thus expected that
this would influence the answers of the interviewees, for
example by omitting admissions of illegal conduct. This
might certainly have influenced some results; however,
surprisingly, most community pharmacists admitted that
they sold ABs without prescriptions even though that is
required by law. Hence, a high degree of truthfulness in
many interviews was obtained.
The data collectors from Albania in particular had diffi-
culties obtaining permission to record their interviews,
which of course reduced the quality of the collected data,
as using data recordings should be emphasized in all
qualitative projects as the prime data collecting technique.
The validity of the evaluation of the study is believed to
be high, as the results were discussed between the SSC
and the pilot facilitators, and all contributed actively and
equally to this publication.
Conclusions
The aim of this paper was to contribute to the knowledge
regarding how to conduct multi-country qualitative re-
search. We propose that supporting previously untrained
local facilitators to collect and analyse data is a means of
achieving valuable research results. We recommend con-
ducting formal discussions between research managers and
local data facilitators to identify inadequacies in project
Kaae et al. Journal of Pharmaceutical Policy and Practice  (2016) 9:20 Page 7 of 10
design. Second, research managers should be prepared to
adjust their protocols, both with respect to the depth and
the breadth of the research, and to balance these aspects of
research quality with the acquired skills of the enrolled
researchers and their available time. Through testing, an
acceptable balance can be achieved. Third, managers and
data collectors should analyse the data together as this can
contribute to highly valid results. Based on our experiences,
we believe that qualitative multi-country research collabor-
ation is possible when these issues are addressed. The
results of this type of work could be of considerable import-
ance for the health of populations worldwide.
Appendix 1: Interview-guide – Patients with
prescription
Introduction
 Introduce yourself and introduce the study. Tell
what the interview will be used for.
 Ask permission to record the interview on tape
 Assure anonymity of the interviewee
 Ask the interviewee to introduce her/him-self,
including age, occupation and where they live
Last face-to-face consultation with physician leading to
prescription for an AB for an upper respiratory tract
infection
Process of diagnosis of AB
 When was the last time you got a prescription for an
upper respiratory tract infection (should be within
the last 3 months)
 What was the situation – what were your
symptoms – for how long?
 Did you have any idea what kind of disease you
were suffering from?
 Did you come here by your own initiative or were
you encouraged by family, colleagues or friends?
 Which doctor did you seek – why this doctor?
 What did you want from the doctor?
 What did you expect from the doctor?
 How did the consultation go? What happened?
What was said – by whom?
 Did the doctor make a diagnosis/examine you? If
yes, how and do you know what the diagnosis was?
Why a specific AB was chosen/Satisfaction with AB
prescription process
 Who chose to use an AB?/Were you involved in
this decision?
 If the doctor solely made the decision – was any
explanation given why to use an AB?
 What AB was chosen? (with regard to product
name, form and strength)
 Were you involved in the decision of what specific
AB to use?
 If yes, please describe how. If the doctor chose the
AB, did he/she explain why to use this specific AB?
 Did the doctor give any instructions on how to use
the AB?
 If yes – which ones? Were the instructions given
written or orally?
 Were you satisfied with the way the consultation
went?
 If yes, why? If no, why not?
Where was the AB purchased/Satisfaction with AB purchase
process
 Where did you purchase the AB prescribed by
your GP?
 Why did you choose this place?
 Please describe the circumstances of the purchase?
What happened? What was said – by whom?
 Were you involved in which specific AB was
purchased? (due to generic substitution or availability
of the drug in the etc.) If yes, please describe how.
 Did the pharmacist give any instructions on how to
use the AB? If yes – what were they?
 Were the instruction given written or orally?
 Were these instructions similar to the ones
provided by the doctor?
 If the pharmacist changed your medicine to
another brand - how did you feel about this?
 Were there any challenges with regard to the
purchase in terms of price; was the drug in stock in
the store, etc.?
 How much medicine did you purchase? Did you
purchase all the necessary AB immediately? If not,
why so?
 Were you satisfied with the way the purchase went?
If yes, why? If no, why not?
Use of AB/Satisfaction with AB use
 When you came home - how did you use the AB?
(How many tablets/dosages per day for how long?)
 Did this use correspond with the instructions given by
the doctor or pharmacist? If yes, why? If no, why not?
 Did you experience any challenges with taking the
AB? If yes, which ones?
 Did the AB alleviate or cure your symptoms? If yes,
please explain how and how quickly?
 Did the original symptoms reoccur?
Kaae et al. Journal of Pharmaceutical Policy and Practice  (2016) 9:20 Page 8 of 10
AB use in general
The last time compared to other times
 Have you had AB prescribed before?
 If yes, approximately how many times? When did it
take place?
 What were the symptoms – for how long?
 Did you have any idea what kind of disease you
were suffering from?
 Did the consultations you had with your doctor at
these times resemble the last time you received a
prescription? Did you also receive a prescription at
these times?
 Was the diagnosis carried out the same way as the
last time you had an AB consultation? If no, describe
how it usually took place.
 Was the way the AB was chosen previously similar
to the last time you had an AB prescription? If no,
please describe how it usually took place.
 Did the doctor give similar instructions about how
to use AB compared to the last time you had an AB
prescription? If no, please describe how it usually
took place.
 Did you suffer previously from any of these
symptoms without seeking a GP? If yes, why (at
these times) not think it was necessary to seek a GP?
 Did the visits to the pharmacy where you previously
purchased your AB prescription resemble the last
time you purchased the AB?
 Were you previously involved in which AB was
purchased in the same way as the last time you
purchased an AB If no, please describe how it usually
took place.
 Did the pharmacists previously give you instructions
about AB use in the same way as the last time you
purchased an AB? If no, please describe how it usually
took place.
 The way you took your AB treatment – does this
resemble how you took AB before (number of days,
compliance with advice of GP or pharmacist, etc.)
Knowledge and attitudes about when to use AB
 Can you explain what AB does in your body?
 From where do you have this knowledge?
 In which situations do you think AB should be
used?
 Why do you think that AB should be given in these
situations?
 Where do you have this knowledge from? Do you ever
discuss these issues with family, friends, colleagues? If
so, do you all agree on these matters?
 Are there situations in which you think AB should
not be used?
 Which situations are these?
 Why do you think that AB should not be used in
these situations? Where do you have this knowledge
from?/Do you ever discuss these issues with family,
friends, colleagues? If so, do you all agree on these
matters?
 Have you ever seen public campaigns addressing
AB use? If yes, what can you remember from these
campaigns? Did the campaigns affect you in any
way? If yes, in which way? If no, why not?
Finalizing interview
 Thank the interviewee for their time.
 Ask if they have any additional comments to what
was said during the interview
 Tell the interviewee what will happen to the
recordings now
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